SAB Biotherapeutics (SABS) Convertible Debt (2022 - 2023)

SAB Biotherapeutics (SABS) has 2 years of Convertible Debt data on file, last reported at $541644.0 in Q2 2023.

• Quarterly Convertible Debt changed N/A year-over-year to $541644.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $541644.0 (changed N/A YoY) and the FY2022 annual result came in at $541644.0, changed N/A from the prior year.
• Convertible Debt held at $541644.0 in Q2 2023, from $541644.0 in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $541644.0 in Q4 2022 to a low of $541644.0 in Q4 2022.